Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individuals

Diabetes Obes Metab. 2022 Jul;24(7):1390-1393. doi: 10.1111/dom.14694. Epub 2022 Apr 6.

Rajiv Agarwal¹, Sibylle Jenny Hauske^{2

3}, David C Wheeler⁴, Kent Doi⁵, Amelie Elsaesser⁶, Ivana Ritter⁶, Dominik Steubl^{2

7}, Christoph Wanner⁸

¹ School of Medicine, Indiana University, Indianapolis, Indiana, USA.
² Boehringer Ingelheim International GmbH, Ingelheim, Germany.
³ Vth Department of Medicine, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
⁴ Centre for Nephrology, University College London, London, UK.
⁵ Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁶ Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
⁷ Department of Nephrology, Faculty of Medicine, Technical University Munich, Munich, Germany.
⁸ Division of Nephrology, Würzburg University Clinic, Würzburg, Germany.

No abstract available

Keywords: SGLT2 inhibitor; empagliflozin; type 2 diabetes.

Publication types